Trials / Completed
CompletedNCT03193138
CardioTOxicity Induced by andRogeNICS and Their Antagonists (TORNICS)
Cardiotoxicity of Androgenic Agonists and Antagonists in the National French Pharmacovigilance Database and EudraCT Database
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,096 (actual)
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere · Academic / Other
- Sex
- Male
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Anti-androgenic therapies relying on peripheral and/or central blockade for the treatment of prostate cancer seems to have an impact on the cardio-vascular system. This study investigates reports of cardiovascular toxicities for treatment including Anatomical Therapeutic Chemical (ATC) classification: sex hormones (G03), hypothalamic hormones (H01C) and sex hormones used in treatment of neoplastic diseases (L02) in the French pharmacovigilance database and European Clinical Trials (EudraCT) database.
Detailed description
Hormone replacement therapies and contraceptive pills are responsible of a wide range of cardio-vascular side effects, particularly thrombo-embolic disorders and ischemic heart disease. The difference of incidence and type of cardio-vascular events between men and women are strongly related to sex hormones. Androgenic agonists and antagonists are used in various indication including prostate cancer or hormone replacement therapies. This study investigates the main characteristics of patients affected by cardiovascular side effects (of which ventricular arrhythmia's, QT prolongation and Torsade de Pointe) imputed to drugs classified as G03, H01C and L02 according to ATC. A causality assessment according to both Begaud's method and the World Health Organization-The Uppsala Monitoring Centre (WHO-UMC) is systematically applied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hormonal therapies: G03, H01C and L02 in the ATC classification | Hormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification |
Timeline
- Start date
- 2017-06-07
- Primary completion
- 2017-06-21
- Completion
- 2017-06-21
- First posted
- 2017-06-20
- Last updated
- 2019-09-25
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03193138. Inclusion in this directory is not an endorsement.